CClinicalTrials.gg
Status unknownNCT04960995BADIAGUpdated Jul 23, 2021

Description of Case of Infection With a New Species of Babesia and Its Molecular Diagnosis

An observational study in Babesiosis, Human, sponsored by University Hospital, Strasbourg, France. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-23.

Sponsored by University Hospital, Strasbourg, France · Observational

The sponsor has not verified this record recently (last verified Jul 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
1
Ages
18 Years and older
Sex
All
01

Study summary

Babesiosis is a potentially very serious infection, but too little known. investigators want to raise their clinical colleagues and remind fellow biologists of the importance of choosing a good molecular diagnosis so as not to give false-negative results.

02

Conditions studied

  • Babesiosis, Human

Keywords

  • Babesiosis
  • BABESIA
  • ZOONOSES
03

In context

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Major subject suffering from severe babesiosis

Inclusion criteria

  • Major subject (≥18 years old)
  • Splenectomized subject
  • Subject with severe babesiosis
  • Subject not having expressed, after information, his opposition to the reuse of his data for the purposes of this research

Exclusion criteria

Exclusion criteria:

  • Subject having expressed opposition to participating in the study
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
1 participant (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. A retrospective study describing a case of infection with a new species of Babesia

    Time frame: The files analyzed retrospectively concern the period from January 01, 2020 to December 31, 2020.

07

Study locations

1 of 1 sites recruiting
  • Parasitology and Medical Mycology Department - Strasbourg University Hospitals
    Strasbourg, 67091, France
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04960995
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Jul 14, 2021
Start date
Jul 10, 2021
Primary completion
Jul 15, 2021 (estimated)
Completion
Jul 15, 2021 (estimated)
Last update
Jul 23, 2021

Study contacts

Alexander PFAFF, MCU-PH
Contact
alexander.pfaff@chru-strasbourg.fr
33 3 69 55 14 45
Saïd CHAYER, PhD, HDR
Contact
said.chayer@chru-strasbourg.fr
33 3 88 11 66 90
Alexander PFAFF, MCU-PH
principal investigator · Parasitology and Medical Mycology Department - Strasbourg University Hospitals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion